Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-07-06 16:00:55
Reporting Period:
Accepted Time:
2020-07-06 16:00:55
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1556263 Syros Pharmaceuticals Inc. SYRS () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253170 Srinivas Akkaraju C/o Syros Pharmaceuticals, Inc.
620 Memorial Drive, Suite 300
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-07-01 4,627 $11.01 1,433,943 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
  1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
  2. These sales were executed in multiple trades at prices ranging from $11.00 to $11.09. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  3. Securities held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein.